Kraig Biocraft Fulfills First Commercial Order, Ramps All Three Production Centers
KBLB sits 57% above its 52-week low of $0.065 on elevated volume (1.9× avg).
Summary
Kraig Biocraft has shipped its first commercial purchase order to a globally recognized sportswear brand, marking the transition from production milestones to actual revenue-generating deliveries. All three production centers are now running simultaneously on staggered schedules, providing continuous output and redundancy. This follows the August production record of 30% growth through the rainy season. The company still reported zero revenue and a going concern warning in its last 10-Q, so this first commercial shipment is a critical step toward validating the business model. Management states production is now focused on addressing commercial market opportunities rather than demonstrating scale.
At the time of this announcement, KBLB was trading at $0.10 on OTC in the Life Sciences sector, with a market capitalization of approximately $108.2M. The 52-week trading range was $0.07 to $0.16. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.